Shares of MEDBOT-B (02252) rose more than 7%. As of the time of writing, the stock was up 7.64%, trading at HK$22.58, with a turnover of HK$20.45 million. On December 24, MEDBOT-B announced that its self-developed bronchoscopy surgical robot, the UniPath™ Electronic Bronchoscopy Surgical Navigation System (UniPath), has officially received approval from the National Medical Products Administration (NMPA). This approval of UniPath by the NMPA represents a milestone breakthrough for the Group in leading the technological and application development within the global surgical robotics field, and it also signifies that domestic surgical robots have achieved systematic full coverage on the key technological path of minimally invasive and non-invasive diagnosis and treatment. With this approval, the number of the Group's products launched in the surgical robotics field has increased to seven, making it the first and currently the only company globally to achieve commercial launches of products across all five major "golden tracks" of surgical robotics. The newly approved UniPath is a non-invasive robotic surgery platform utilizing natural orifices. It features an ultra-flexible, ultra-slim snake-like robotic catheter that can navigate through the body's natural passages, accessing hard-to-reach narrow lesion spaces without any external incisions, which is highly significant for the early diagnosis and treatment of early-stage lesions like pulmonary micro-nodules.